Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shunichiro Orihara"'
Autor:
Sakue Masuda, Yoshinori Imamura, Chikamasa Ichita, Ryuhei Jinushi, Jun Kubota, Karen Kimura, Makomo Makazu, Ryo Sato, Makoto Kako, Masahiro Kobayashi, Haruki Uojima, Masataka Taguri, Shunichiro Orihara, Kazuya Koizumi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The standard treatment duration for acute cholangitis (AC) involves a 4–7-day antimicrobial treatment post-biliary drainage; however, recent studies have suggested that a ≤ 2–3 days is sufficient. However, clinical practice frequently
Externí odkaz:
https://doaj.org/article/2d0c331cc7c5468bbd611f7ef5cd0585
Autor:
Yasuyuki Takada, Kazuki Shiina, Shunichiro Orihara, Yoshifumi Takata, Takamichi Takahashi, Junya Kani, Takahiro Kusume, Muryo Terasawa, Hiroki Nakano, Yukio Saitoh, Yoshinao Yazaki, Hirofumi Tomiyama, Taishiro Chikamori, Kazuhiro Satomi
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 54, Iss , Pp 101490- (2024)
Background: Obstructive sleep apnea (OSA) is one of the risk factors for atrial fibrillation (AF). However, the mechanism underlying the atrial structural and electro-anatomical remodeling by OSA has not yet been clearly elucidated. Methods: This stu
Externí odkaz:
https://doaj.org/article/9ee40394015d4c339394f1c3842dcdde
Publikováno v:
Contemporary Clinical Trials Communications, Vol 36, Iss , Pp 101210- (2023)
Background: Sample size re-estimation (SSR) is a method used to recalculate sample size during clinical trial conduct to address a lack of adequate information and can have a significant impact on study size, duration, resources, and cost. Few studie
Externí odkaz:
https://doaj.org/article/11afed4e414240c2bceea79f31b68429
Publikováno v:
Behaviormetrika. 50:241-262
Publikováno v:
The International Journal of Biostatistics.
Li and Greene (A weighting analogue to pair matching in propensity score analysis. Int J Biostat 2013;9:215–34) propose that estimates derived by the matching weight (MW) estimator are similar to those derived by the one-to-one propensity score mat
Autor:
Noriyuki Namba, Takuo Kubota, Koji Muroya, Hiroyuki Tanaka, Masanori Kanematsu, Masahiro Kojima, Shunichiro Orihara, Hironori Kanda, Yoshiki Seino, Keiichi Ozono
Objective Burosumab, an anti-fibroblast growth factor 23 antibody, was recently approved for the treatment of X-linked hypophosphatemia (XLH). We evaluated the safety and efficacy of burosumab in pediatric XLH patients. Methods This open-label, phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d651a069f7068d6740d10c1c3c436611
Autor:
Shunichiro Orihara, Etsuo Hamada
Publikováno v:
Communications in Statistics - Theory and Methods. 48:462-478
Double robust estimators have double the chance of being a consistent estimator of a causal effect in binary treatments cases. In this paper, we proposed an estimator of a causal effect for general...
Autor:
Shunichiro Orihara, Etsuo Hamada
Publikováno v:
Statistics & Probability Letters. 168:108951
In observational studies, propensity score methods are useful for estimating causal effects. We propose a new method for selecting the optimal number of strata for subclassification on the propensity score. The proposed method achieves “optimality